Literature DB >> 3008997

Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies.

S Fargion, D Carney, J Mulshine, S Rosen, P Bunn, P Jewett, F Cuttitta, A Gazdar, J Minna.   

Abstract

Using immunohistochemistry, radiobinding, and indirect immunofluorescence assays, seven distinct cell surface antigens, detected by monoclonal antibodies, were analyzed for the degree of homogeneity or heterogeneity of antigen expression on a panel of human small cell lung cancers. The panel included 7 tumors taken directly from patients, 21 established cell lines (9 of which were derived from different metastatic sites of 3 patients), and 33 clonal derivatives of 3 lines. With all assays, considerable heterogeneity of antigen expression between tumors from different patients was observed. In both fresh tumors and in cell lines, as well as in cell lines established from different metastatic sites in an individual patient, we observed intratumor heterogeneity finding antigen positive and negative cells and variation in antigenic density, by immunohistochemistry and indirect immunofluorescence assays. Antigenic expression was not cell cycle dependent. In addition, when cell lines or patient samples expressing antigen positive and antigen negative tumor cells were cloned, heterogeneity of antigenic expression was still present in the clonal lines. This suggests that either the expression of the antigen was not heritable and/or the ability to regenerate antigenic heterogeneity is an intrinsic property of the tumor cells. The heterogeneity of antigen expression on lung cancer cells has significant implications for the use of these and other monoclonal antibodies in the study and therapy of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008997

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

Authors:  Yan Ting Shue; Jing Shan Lim; Julien Sage
Journal:  Transl Lung Cancer Res       Date:  2018-02

2.  Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.

Authors:  K Beiske; A T Myklebust; S Aamdal; R Langholm; E Jakobsen; O Fodstad
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

3.  Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.

Authors:  T Nakai; H Sakahara; K Endo; M Shirato; H Kobayashi; M Hosono; T Saga; M Sakamoto; J Konishi
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

4.  Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes.

Authors:  J W Bulte; K G Go; F Zuiderveen; T H The; L de Leij
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

5.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Authors:  Kipp Weiskopf; Nadine S Jahchan; Peter J Schnorr; Sandra Cristea; Aaron M Ring; Roy L Maute; Anne K Volkmer; Jens-Peter Volkmer; Jie Liu; Jing Shan Lim; Dian Yang; Garrett Seitz; Thuyen Nguyen; Di Wu; Kevin Jude; Heather Guerston; Amira Barkal; Francesca Trapani; Julie George; John T Poirier; Eric E Gardner; Linde A Miles; Elisa de Stanchina; Shane M Lofgren; Hannes Vogel; Monte M Winslow; Caroline Dive; Roman K Thomas; Charles M Rudin; Matt van de Rijn; Ravindra Majeti; K Christopher Garcia; Irving L Weissman; Julien Sage
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

6.  Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies.

Authors:  S K Liao; C Meranda; B P Avner; T Romano; S Husseini; B Kimbro; R K Oldham
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Small cell lung cancer.

Authors:  R C Leonard
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

8.  Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

Authors:  Marius Ilie; Shirin Khambata-Ford; Christiane Copie-Bergman; Lingkang Huang; Jonathan Juco; Veronique Hofman; Paul Hofman
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 9.  Radioimmunotherapy of malignancy using antibody targeted radionuclides.

Authors:  L M Cobb; J L Humm
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

10.  Detailed characterization of a high-molecular-weight glycoprotein secreted by lung cancer cells.

Authors:  N Nonaka; K Manaka; K Kobayashi; H Hirai
Journal:  Jpn J Cancer Res       Date:  1993-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.